Owner Investor / Financier Operator Developer Offtaker
GlaxoSmithKline plc (GSK) is a global biopharmaceutical company headquartered in the United Kingdom. The company researches, develops, manufactures, and markets vaccines and specialty medicines, with core areas including infectious diseases, HIV (through majority-owned ViiV Healthcare), respiratory and immunology, and oncology. GSK operates extensive R&D programs and clinical development activities supported by a worldwide network of laboratories and regulatory engagements. In 2022, it demerged its consumer healthcare business into Haleon, focusing GSK on prescription medicines and vaccines.
For the chemical and life sciences value chain, GSK’s operations span small-molecule synthesis, biologics, and large-scale vaccine production, encompassing active pharmaceutical ingredient (API) and intermediate manufacturing for its own products, formulation, and fill-finish capabilities. The company maintains global manufacturing sites and supply chains adhering to GMP and other international quality standards, and collaborates with partners and institutions to advance new therapies and improve production reliability.
Also known as GlaxoSmithKline.
chemXplore tracks 4 projects involving GSK, of which one is active.
Besides this one, the record holds 3 completed projects.
Closest to start-up first.
The 3 that are completed, on hold or cancelled are in the record. See all 4 in chemXplore
The recommendation covers people vaccinated at least two years earlier; EU authorisation is still pending.
Long-term Hibsago data and efimosfermin Phase II fibrosis signals headline 21 abstracts at AASLD (5–9 Nov, Denver). Findings span functional cure durability, HBsAg predictors and retreatment modelling.
Specialty Medicines and new launches drove mid-single‑digit sales growth and core profit expansion, while a £328m restructuring charge cut total operating profit and EPS.
Phase III ARTEMIS‑011 showed median PFS 5.5 vs 1.4 months (HR 0.33); safety showed high rates of grade ≥3 TRAEs with Ris‑Rez versus chemotherapy.
76% of evaluable patients had no detectable cancer after dostarlimab monotherapy; responders show no recurrences after more than two years; safety consistent with known profile.
Phase Ib BEHOLD‑1 reports durable responses and 11.1‑month median PFS at the selected phase III dose; safety predominantly haematologic with most grade ≥3 events.
FDA approves a six-month antisense-oligonucleotide therapy with option for self-administration; phase III showed 19% functional cure in patients with HBsAg ≤3000 IU/ml.
First FDA‑approved immunotherapy for this biomarker-defined rectal cancer; AZUR-1 shows high sustained clinical complete response rates and no recurrences among responders.
active all projects
